|
1
|
Hoffman PC, Mauer AM and Vokes EE: Lung
cancer. Lancet. 355:479–485. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dumitru CD, Ceci JD, Tsatsanis C,
Kontoyiannis D, Stamatakis K, Lin JH, Patriotis C, Jenkins NA,
Copeland NG, Kollias G and Tsichlis PN: TNF-alpha induction by LPS
is regulated posttranscriptionally via a TPL2/ERK-dependent
pathway. Cell. 103:1071–1083. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jager J, Gremeaux T, Gonzalez T, Bonnafous
S, Debard C, Laville M, Vidal H, Tran A, Gual P, Le
Marchand-Brustel Y, et al: TPL2 kinase is upregulated in adipose
tissue in obesity and may mediate interleukin-1beta and tumor
necrosis factor-{alpha} effects on extracellular signal-regulated
kinase activation and lipolysis. Diabetes. 59:61–70. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Perugorria MJ, Murphy LB, Fullard N,
Chakraborty JB, Vyrla D, Wilson CL, Oakley F, Mann J and Mann DA:
Tumor progression locus 2/Cot is required for activation of
extracellular regulated kinase in liver injury and toll-like
receptor-induced TIMP-1 gene transcription in hepatic stellate
cells in mice. Hepatology. 57:1238–1249. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Martel G, Bérubé J and Rousseau S: The
protein kinase TPL2 is essential for ERK1/ERK2 activation and
cytokine gene expressionin airway epithelial cells exposed to
pathogen-associated molecular patterns (PAMPs). PLoS One.
8:e591162013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hirschhorn J, Mohanty S and Bhat NR: The
role of tumor progression locus 2 protein kinase in glial
inflammatory response. J Neurochem. 128:919–926. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu YP, Landsittel D, Jing L, Nelson J, Ren
B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, et al: Gene
expression alterations in prostate cancer predicting tumor
aggression and preceding development of malignancy. J Clin Oncol.
22:2790–2799. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hatziapostolou M, Polytarchou C,
Panutsopulos D, Covic L and Tsichlis PN: Proteinase-activated
receptor-1-triggered activation of tumor progression locus-2
promotes actin cytoskeleton reorganization and cell migration.
Cancer Res. 68:1851–1861. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang Y, Wang X, Hawkins CA, Chen K,
Vaynberg J, Mao X, Tu Y, Zuo X, Wang J, Wang YX, et al: Structural
basis of focal adhesion localization of LIM-only adaptor PINCH by
integrin-linked kinase. J Biol Chem. 284:5836–5844. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ohara R, Hirota S, Onoue H, Nomura S,
Kitamura Y and Toyoshima K: Identification of the cells expressing
cot proto-oncogene mRNA. J Cell Sci. 108:97–103. 1995.PubMed/NCBI
|
|
11
|
Christoforidou AV, Papadaki HA, Margioris
AN, Eliopoulos GD and Tsatsanis C: Expression of the TPL2/Cot
oncogene in human T-cell neoplasias. Mol Cancer. 3:342004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sourvinos G, Tsatsanis C and Spandidos DA:
Overexpression of the Tpl-2/Cot oncogene in human breast cancer.
Oncogene. 18:4968–4973. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Krcova Z, Ehrmann J, Krejci V, Eliopoulos
A and Kolar Z: Tpl-2/Cot and COX-2 in breast cancer. Biomed Pap Med
Fac Univ Palacky Olomouc Czech Repub. 152:21–25. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee HW, Joo KM, Lim JE, Cho HJ, Cho HJ,
Park MC, Seol HJ, Seo SI, Lee JI, Kim S, et al: TPL2 kinase impacts
tumor growth and metastasis of clear cell renal cell carcinoma. Mol
Cancer Res. 11:1375–1386. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gkirtzimanaki K, Gkouskou KK, Oleksiewicz
U, Nikolaidis G, Vyrla D, Liontos M, Pelekanou V, Kanellis DC,
Evangelou K, Stathopoulos EN, et al: TPL2 kinase is a suppressor of
lung carcinogenesis. Proc Natl Acad Sci USA. 110:pp. E1470–E1479.
2013; View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Baltimore D, Boldin MP, O'Connell RM, Rao
DS and Taganov KD: MicroRNAs: New regulators of immune cell
development and function. Nat Immunol. 9:839–845. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xiao C and Rajewsky K: MicroRNA control in
the immune system: Basic principles. Cell. 136:26–36. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gao W, Yu Y, Cao H, Shen H, Li X, Pan S
and Shu Y: Deregulated expression of miR-21, miR-143 and miR-181a
in non small cell lung cancer is related to clinicopathologic
characteristics or patient prognosis. Biomed Pharmacother.
64:399–408. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:pp. 2257–2261.
2006; View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ,
Van Schil PE, et al: International association for the study of
lung cancer/American thoracic society/European respiratory society
international multidisciplinary classification of lung
adenocarcinoma. J Thorac Oncol. 6:244–85. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Travis WD, Brambilla E, Noguchi M,
Nicholson A, Geisinger K, Yatabe Y, Ishikawa Y, Wistuba I, Flieder
DB, Franklin W, et al: Diagnosis of lung cancer in small biopsies
and cytology: Implications of the 2011 international association
for the study of lung cancer/American thoracic society/European
respiratory society classification. Arch Pathol Lab Med.
137:668–684. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-(Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Decicco-Skinner KL, Trovato EL, Simmons
JK, Lepage PK and Wiest JS: Loss of tumor progression locus 2
(tpl2) enhances tumorigenesis and inflammation in two-stage skin
carcinogenesis. Oncogene. 30:389–1397. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Asimakopoulos F, Kim J, Denu RA, Hope C,
Jensen JL, Ollar SJ, Hebron E, Flanagan C, Callander N and Hematti
P: Macrophages in multiple myeloma: Emerging concepts and
therapeutic implications. Leuk Lymphoma. 54:2112–2121. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Krol J, Loedige I and Filipowicz W: The
widespread regulation of microRNA biogenesis, function and decay.
Nat Rev Genet. 11:597–610. 2010.PubMed/NCBI
|
|
27
|
Schetter AJ, Heegaard NH and Harris CC:
Inflammation and cancer: Interweaving microRNA, free radical,
cytokine and p53 pathways. Carcinogenesis. 31:37–49. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fujita K, Mondal AM, Horikawa I, Nguyn GH,
Kumamoto K, Sohn JJ, Bowman ED, Mathe EA, Schetter AJ, Pine SR, et
al: p53isoforms Delta133p53 and p53beta are endogenous regulators
of replicative cellular senescence. Nat Cell Biol. 11:1135–1142.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Saito M, Schetter AJ, Mollerup S, Kohno T,
Skaug V, Bowman ED, Mathé EA, Takenoshita S, Yokota J, Haugen A and
Harris CC: The association of microRNA expression with prognosis
and progression in early-stage, non small cell lung adenocarcinoma:
A retrospective analysis of three cohorts. Clin Cancer Res.
17:1875–1882. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yanaihara N, Caplen N, Bowman E, Seike M,
Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et
al: Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Capodanno A, Boldrini L, Proietti A, Alì
G, Pelliccioni S, Niccoli C, D'Incecco A, Cappuzzo F, Chella A,
Lucchi M, et al: Let-7g and miR-21 expression in non-small cell
lung cancer: Correlation with clinicopathological and molecular
features. Int J Oncol. 43:765–774. 2013.PubMed/NCBI
|
|
32
|
Liu XG, Zhu WY, Huang YY, Ma LN, Zhou SQ,
Wang YK, Zeng F, Zhou JH and Zhang YK: High expression of serum
miR-21 and tumor miR-200c associated with poor prognosis in
patients with lung cancer. Med Oncol. 29:618–626. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gao W, Shen H, Lui L, Xu J, Xu J and Shu
Y: MiR-21 overexpression in human primary squamous cell lung
carcinoma is associated with poor patient prognosis. J Cancer Res
Clin Oncol. 137:557–566. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Markou A, Tsaroucha EG, Kaklamanis L,
Fotinou M, Georgoulias V and Lianidou ES: Prognostic value of
mature microRNA-21 and microRNA-205 overexpression in non-small
cell lung cancer by quantitative real-time RT-PCR. Clin Chem.
54:1696–1704. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Voortman J, Goto A, Mendiboure J, Sohn JJ,
Schetter AJ, Saito M, Dunant A, Pham TC, Petrini I, Lee A, et al:
MicroRNA expression and clinical outcomes in patients treated with
adjuvant chemotherapy after complete resection of non-small cell
lung carcinoma. Cancer Res. 70:8288–8298. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gu J, Lu C, Guo J, Chen L, Chu Y, Ji Y and
Ge D: Prognostic significance of the IASLC/ATS/ERS classification
in Chinese patients-A single institution retrospective study of 292
lung adenocarcinoma. J Surg Oncol. 107:474–480. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Russell PA, Wainer Z, Wright GM, Daniels
M, Conron M and Williams RA: Does lung adenocarcinoma subtype
predict patient survival?: A clinic-pathologic study based on the
new international association for the study of lung cancer/American
thoracic society/European respiratory society international
multidisciplinary lung adenocarcinoma classification. J Thorac
Oncol. 6:1496–1504. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Solis LM, Behrens C, Raso MG, Lin HY,
Kadara H, Yuan P, Galindo H, Tang X, Lee JJ, Kalhor N, et al:
Histological patterns and molecular characteristics of lung
adenocarcinoma associated with clinical outcome. Cancer.
118:2889–2899. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Araki K, Kidokoro Y, Hosoya K, Wakahara M,
Matsuoka Y, Takagi Y, Haruki T, Miwa K, Taniguchi Y, Horie S and
Nakamura H: Excellent prognosis of lepidic-predominant lung
adenocarcinoma: Low incidence of lymphatic vessel invasion as a key
factor. Anticancer Res. 34:3153–3156. 2014.PubMed/NCBI
|
|
40
|
Okamoto T, Maruyama R, Suemitsu R, Aoki Y,
Wataya H, Kojo M and Ichinose Y: Prognostic value of the
histological subtype in completely resected non-small cell lung
cancer. Interact Cardiovasc Thorac Surg. 5:362–366. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yatabe Y, Mitsudomi T and Takahashi T:
TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol.
26:767–773. 2002. View Article : Google Scholar : PubMed/NCBI
|
